Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

Numinus reports its Q2 2021 results. Cash balance of CAD$28.5 million. Net loss of CAD$4.2 million.

Read more
COMPASS Pathways launches proposed public offering

Compass Pathways plans to issue 4,000,000 new shares via prospectus, with an option to sell an additional 600,000 shares.

Read more
Wesana Health and Debut Announce Receipt of Conditional Approval for CSE Listing

Wesana Health obtains conditional approval from the CSE to commence trading, via RTO with Debut Diamonds (CSE:DDI).

Read more
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.

Read more
Second-Chance Buying Opportunity With Psychedelic Stock Warrants

In 2020, investors were able to reap spectacular returns from psychedelic stock warrants. With a new rally starting in the sector, a there is a NEW opportunity in these warrants.

Read more
Red Light Holland and Halo Collective Create Red Light Oregon, Inc. – Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market

Red Light Holland seeks to enter the (legal) medicinal psilocybin market in Oregon.

Read more
MindMed Begins Trading on Nasdaq

MindMed Inc commences trading on the NASDAQ exchange under the symbol “MNMD”.

Read more
Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

Psyched Wellness continues pre-clinical work on its AME-1 extract.

Read more
Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility

Optimi Health gets closer to completion of its 20,000 sq. ft. production and research facility in British Columbia.

Read more

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )